Pediatric Graves’ disease: management in the post-propylthiouracil Era

International Journal of Pediatric Endocrinology

Scott A Rivkees¹ 

[1] Department of Pediatrics, University of Florida College of Medicine, 1600 SW Archer Road – Room R1-118, Gainesville, FL, USA

关键词: Hepatotoxicity;    Thyroidectomy;    Radioactive iodine;    Propylthiouracil;    Methimazole;    Hyperthyroidism;    Thyroid;   

Others  :  1135856
DOI  :  10.1186/1687-9856-2014-10

 received in 2014-04-10, accepted in 2014-06-04,  发布年份 2014

【 摘 要 】

The most prevalent cause of thyrotoxicosis in children is Graves’ disease (GD), and remission occurs only in a modest proportion of patients. Thus most pediatric patients with GD will need treatment with radioactive iodine (RAI; ¹³¹I) or surgical thyroidectomy. When antithyroid drugs (ATDs) are prescribed, only methimazole (MMI) should be administered, as PTU is associated with an unacceptable risk of severe liver injury. If remission does not occur following ATD therapy, ¹³¹I or surgery should be contemplated. When ¹³¹I is administered, dosages should be greater than 150 uCi/gm of thyroid tissue, with higher dosages needed for large glands. Considering that there will be low-level whole body radiation exposure associated with ¹³¹I, this treatment should be avoided in young children. When surgery is performed near total or total-thyroidectomy is the recommended procedure. Complications for thyroidectomy in children are considerably higher than in adults, thus an experienced thyroid surgeon is needed when children are operated on. Most importantly, the care of children with GD can be complicated and requires physicians with expertise in the area.

【 授权许可】

   
2014 Rivkees; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Abraham-Nordling M, Torring O, Lantz M, Hallengren B, Ohrling H, Lundell G, Calissendorff J, Jörneskog G, Wallin G: Incidence of hyperthyroidism in Stockholm, Sweden, 2003–2005. Eur J Endocrinol/Eur Fed Endocr Soc 2008, 158:823-827.
• [2]Conference Proceeding: Hepatic Toxicity Following Treatment for Pediatric Graves’ Disease Meeting: October 28, 2008. Conference Proceeding: Hepatic Toxicity Following Treatment for Pediatric Graves’ Disease Meeting: October 28, 2008. http://bpca.nichd.nih.gov/outreach/index.cfm webcite. 2009. (Accessed January 14, 2009, at http://bpca.nichd.nih.gov/outreach/index.cfm webcite.)
• [3]Smith J, Brown RS: Persistence of thyrotropin (TSH) receptor antibodies in children and adolescents with Graves' disease treated using antithyroid medication. Thyroid 2007, 17:1103-1107.
• [4]Rivkees SA, Sklar C, Freemark M: Clinical review 99: The management of Graves' disease in children, with special emphasis on radioiodine treatment. J Clin Endocrinol Metabol 1998, 83:3767-3776.
• [5]Weetman AP: Grave's disease 1835–2002. Horm Res 2003, 59(Suppl 1):114-118.
• [6]Chapman EM: History of the discovery and early use of radioactive iodine. JAMA 1983, 250:2042-2044.
• [7]Cooper DS: Antithyroid drugs. N Engl J Med 2005, 352:905-917.
• [8]Talbot NB SE, McArthur JW, Crawford JD: Functional Endocrinology: from Birth to Adolescence. Cambridge: Harvard University Press; 1952:1-51.
• [9]Cooper DS: Antithyroid drugs for the treatment of hyperthyroidism caused by Graves' disease. Endocrinol Metab Clin North Am 1998, 27:225-247.
• [10]Rivkees SA: 63 Years and 715 Days to the “Boxed Warning”: Unmasking of the Propylthiouracil Problem. Int J Pediatr Endocrinol 2010., 2010Article ID 658267, 3 pages, 2010. doi:10.1155/2010/658267
• [11]Rivkees SA, Mattison DR: Ending propylthiouracil-induced liver failure in children. N Engl J Med 2009, 360:1574-1575.
• [12]Rivkees SA, Mattison DR: Propylthiouracil (PTU) Hepatoxicity in Children and Recommendations for Discontinuation of Use. Int J Pediatr Endocrinol 2009, 2009:132041.
• [13]Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P: Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl 2004, 10:1018-1023.
• [14]Nakamura H, Noh JY, Itoh K, Fukata S, Miyauchi A, Hamada N: Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves' disease. J Clin Endocrinol Metab 2007, 92:2157-2162.
• [15]Nicholas WC, Fischer RG, Stevenson RA, Bass JD: Single daily dose of methimazole compared to every 8 hours propylthiouracil in the treatment of hyperthyroidism. South Med J 1995, 88:973-976.
• [16]Sato H, Harada S, Yokoya S, Tanaka T, Asayama K, Mori M, Sasaki N: Treatment for childhood-onset Graves' disease in Japan: results of a nationwide questionnaire survey of pediatric endocrinologists and thyroidologists. Thyroid 2007, 17:67-72.
• [17]Cassio A, Corrias A, Gualandi S, Tato' L, Cesaretti G, Volta C, Weber G, Bona G, Cappa M, Bal M, Bellone J, Cicognani A: Influence of gender and pubertal stage at diagnosis on growth outcome in childhood thyrotoxicosis: results of a collaborative study. Clin Endocrinol (Oxf) 2006, 64:53-57.
• [18]Dotsch J, Rascher W, Dorr HG: Graves disease in childhood: a review of the options for diagnosis and treatment. Paediatr Drugs 2003, 5:95-102.
• [19]Dotsch J, Siebler T, Hauffa BP, Doeker B, Andler W, Bettendorf M, Heinrich U, Gohlke B, Albers N, Willgerodt H, Kiess W: Diagnosis and management of juvenile hyperthyroidism in Germany: a retrospective multicenter study. J Pediatric Endocrinol 2000, 13:879-885.
• [20]Slyper AH, Wyatt D, Boudreau C: Effective methimazole dose for childhood Grave's disease and use of free triiodothyronine combined with concurrent thyroid-stimulating hormone level to identify mild hyperthyroidism and delayed pituitary recovery. J Pediatr Endocrinol Metab 2005, 18:597-602.
• [21]Abraham P, Avenell A, Watson WA, Park CM, Bevan JS: Antithyroid drug regimen for treating Graves' hyperthyroidism. Cochrane Database Syst Rev 2005, 2:CD003420.
• [22]Razvi S, Vaidya B, Perros P, Pearce SH: What is the evidence behind the evidence-base? The premature death of block-replace antithyroid drug regimens for Graves' disease. Eur J Endocrinol/Eur Fed Endocr Soc 2006, 154:783-786.
• [23]Cooper DS, Goldminz D, Levin AA, Ladenson PW, Daniels GH, Molitch ME, Ridgway EC: Agranulocytosis associated with antithyroid drugs. Effects of patient age and drug dose. Ann Intern Med 1983, 98:26-29.
• [24]Woeber KA: Methimazole-induced hepatotoxicity. Endocr Pract 2002, 8:222-224.
• [25]Rivkees SA, Stephenson K, Dinauer C: Adverse events associated with methimazole therapy of graves' disease in children. Int J Pediatr Endocrinol 2010, 2010:176970.
• [26]Tajiri J, Noguchi S: Antithyroid drug-induced agranulocytosis: how has granulocyte colony-stimulating factor changed therapy? Thyroid 2005, 15:292-297.
• [27]Harper L, Chin L, Daykin J, Allahabadia A, Heward J, Gough SC, Savage CO, Franklyn JA: Propylthiouracil and carbimazole associated-antineutrophil cytoplasmic antibodies (ANCA) in patients with Graves' disease. Clin Endocrinol (Oxf) 2004, 60:671-675.
• [28]Guma M, Olive A, Juan M, Salinas I: ANCA antibodies in Graves' disease. Ann Rheum Dis 2002, 61:90-91.
• [29]Radice A, Sinico RA: Antineutrophil cytoplasmic antibodies (ANCA). Autoimmunity 2005, 38:93-103.
• [30]Poomthavorn P, Mahachoklertwattana P, Tapaneya-Olarn W, Chuansumrit A, Chunharas A: Antineutrophilic cytoplasmic antibody-positive systemic vasculitis associated with propylthiouracil therapy: report of 2 children with Graves' disease. J Med Assoc Thai 2002, 85(Suppl 4):S1295-S1301.
• [31]Fujieda M, Suzuki K, Sato H, Hattori M, Wada N, Tsuchiya M, Okamoto N, Murata T, Matsudaira M, Shimizu M, Ohta K, Naruse K, Sugihara S, Wakiguchi H: Epitope analysis of myeloperoxidase-specific antineutrophil cytoplasmic autoantibodies (MPO-ANCA) in childhood onset Graves' disease treated with propylthiouracil. Clin Nephrol 2005, 63:437-445.
• [32]Merkel PA: Drugs associated with vasculitis. Curr Opin Rheumatol 1998, 10:45-50.
• [33]Hamburger JI: Management of hyperthyroidism in children and adolescents. J Clin Endocrinol Metab 1985, 60:1019-1024.
• [34]Glaser NS, Styne DM: Predictors of early remission of hyperthyroidism in children. J Clin Endocrinol Metab 1997, 82:1719-1726.
• [35]Glaser NS, Styne DM: Predicting the likelihood of remission in children with Graves' disease: a prospective, multicenter study. Pediatrics 2008, 121:e481-e488.
• [36]Kaguelidou F, Alberti C, Castanet M, Guitteny MA, Czernichow P, Leger J: Predictors of Autoimmune Hyperthyroidism Relapse in Children after Discontinuation of Antithyroid Drug Treatment. J Clin Endocrinol Metab 2008, 10:3817-3826.
• [37]Leger J, Gelwane G, Kaguelidou F, Benmerad M, Alberti C: Positive impact of long-term antithyroid drug treatment on the outcome of children with Graves' disease: national long-term cohort study. J Clin Endocrinol Metab 2012, 97:110-119.
• [38]Weetman AP: Graves' hyperthyroidism: how long should antithyroid drug therapy be continued to achieve remission? Nat Clin Pract Endocrinol Metab 2006, 2:2-3.
• [39]Allannic H, Fauchet R, Orgiazzi J, Madec AM, Genetet B, Lorcy Y, Le Guerrier AM, Delambre C, Derennes V: Antithyroid drugs and Graves' disease: a prospective randomized evaluation of the efficacy of treatment duration. J Clin Endocrinol Metab 1990, 70:675-679.
• [40]Garcia-Mayor RV, Paramo C, Luna Cano R, Perez Mendez LF, Galofre JC, Andrade A: Antithyroid drug and Graves' hyperthyroidism. Significance of treatment duration and TRAb determination on lasting remission. J Endocrinol Invest 1992, 15:815-820.
• [41]Maugendre D, Gatel A, Campion L, Massart C, Guilhem I, Lorcy Y, Lescouarch J, Herry JY, Allannic H: Antithyroid drugs and Graves' disease–prospective randomized assessment of long-term treatment. Clin Endocrinol (Oxf) 1999, 50:127-132.
• [42]Shulman DI, Muhar I, Jorgensen EV, Diamond FB, Bercu BB, Root AW: Autoimmune hyperthyroidism in prepubertal children and adolescents: comparison of clinical and biochemical features at diagnosis and responses to medical therapy. Thyroid 1997, 7:755-760.
• [43]Ma C, Kuang A, Xie J, Liu G: Radioiodine treatment for pediatric Graves' disease. Cochrane Database Syst Rev 2008, 3:CD006294.
• [44]Lippe BM, Landaw EM, Kaplan SA: Hyperthyroidism in children treated with long term medical therapy: twenty-five percent remission every two years. J Clin Endocrinol Metab 1987, 64:1241-1245.
• [45]Gruneiro-Papendieck L, Chiesa A, Finkielstain G, Heinrich JJ: Pediatric Graves' disease: outcome and treatment. J Pediatr Endocrinol Metab 2003, 16:1249-1255.
• [46]Lazar L, Kalter-Leibovici O, Pertzelan A, Weintrob N, Josefsberg Z, Phillip M: Thyrotoxicosis in prepubertal children compared with pubertal and postpubertal patients. J Clin Endocrinol Metab 2000, 85:3678-3682.
• [47]Vitti P, Rago T, Chiovato L, Pallini S, Santini F, Fiore E, Rocchi R, Martino E, Pinchera A: Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment. Thyroid 1997, 7:69-375.
• [48]Bouma DJ, Kammer H, Greer MA: Follow-up comparison of short-term versus 1-year antithyroid drug therapy for the thyrotoxicosis of Graves' disease. J Clin Endocrinol Metab 1982, 55:1138-1142.
• [49]Greer MA, Kammer H, Bouma DJ: Short-term antithyroid drug therapy for the thyrotoxicosis of Graves' disease. N Engl J Med 1977, 297:173-176.
• [50]Bing RF: Early remission in thyrotoxicosis produced by short coursed of treatment. Acta Endocrinol Suppl 1982, 100:221-223.
• [51]Salpeter SR, Ormiston TM, Salpeter EE: Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis. Ann Intern Med 2002, 137:715-725.
• [52]Wintergerst KA, Rogers ES, Foster MB: Hyperthyroidism presenting with hyperglycemia in an adolescent female. J Pediatr Endocrinol Metab 2011, 24:385-387.
• [53]Gomez Cruz MJ, Jabbar M, Saini N, Eng D, Crawford B, Vazquez DM, Menon R, Chen M: Severe hypoglycemia secondary to methimazole-induced insulin autoimmune syndrome in a 16 year old African-American male. Pediatr Diabetes 2012, 13:652-655.
• [54]Benavides VC, Rivkees SA: Myopathy associated with acute hypothyroidism following radioiodine therapy for graves disease in an adolescent. Int J Pediatr Endocrinol 2010., 2010doi:10.1155/2010/717303. Epub 2010 Sep 14
• [55]van Veenendaal NR, Rivkees SA: Treatment of pediatric Graves' disease is associated with excessive weight gain. J Clin Endocrinol Metab 2011, 96:3257-3263.
• [56]Williams ED: Biological effects of radiation on the thyroid. In The Thyroid. Edited by Braverman LE, Utiger RD. Phildelphia: J.B. Lippincott Co; 1986:421-436.
• [57]Hertz BE, Schuller KE: Saul Hertz, Md (1905–1950): A Pioneer in the Use of Radioactive Iodine. Endocr Pract 2010, 16:713-715.
• [58]Sheline GE, McCormack KR, Galante M: Thyroid nodules occurring late after treatment of thryotoxicosis with radioiodine. J Clin Endocrinol Metab 1962, 22:8-17.
• [59]Dobyns BM, Sheline GE, Workman JB, Tompkins EA, McConahey WM, Becker DV: Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism: a report of the Cooperative Thyrotoxicosis Therapy Follow-up Study. J Clin Endocrinol Metab 1974, 38:976-998.
• [60]Goolden AWG, Davey JB: The ablation of normal thyroid tissue with iodine-131. Br J Radiol 1963, 36:340-345.
• [61]Maxon HR, Thomas SR, Hertzberg VS, Kereiakes JG, Chen IW, Sperling MI, Saenger EL: Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med 1983, 309:937-941.
• [62]Levy WM, Schumacher OP, Gupta M: Treatment of childhood Graves' disease. A review with emphasis on radioiodine treatment. Cleveland Clin J Med 1988, 55:373-382.
• [63]Peters H, Fischer C, Bogner U, Reiners C, Schleusener H: Treatment of Graves' hyperthyroidism with radioiodine: results of a prospective randomized study. Thyroid 1997, 7:247-251.
• [64]Graham GD, Burman KD: Radioiodine treatment of Graves' disease. An assessment of its potential risks. Ann Intern Med 1986, 105:900-905.
• [65]Peters H, Fischer C, Bogner U, Reiners C, Schleusener H: Radioiodine therapy of Graves' hyperthyroidism: standard vs. calculated 131 iodine activity. Results from a prospective, randomized, multicentre study. Eur J Clin Invest 1995, 25:186-193.
• [66]Becker DV, Hurly JR: Complications of radioiodine treatment of hyperthyroidism. Semin Nucl Med 1971, 1:442-460.
• [67]Kadmon PM, Noto RB, Boney CM, Goodwin G, Gruppuso PA: Thyroid storm in a child following radioactive iodine (RAI) therapy: a consequence of RAI versus withdrawal of antithyroid medication. J Clin Endocrinol Metab 2001, 86:1865-1867.
• [68]Refetoff S, Demeester-Mirkine N, Ermans AM, De Groot LJ: Rapid control of thyrotoxicosis with combined 131I, anthithyroid drugs and KI therapy. J Nucl Med Allied Sci 1977, 21:23-29.
• [69]Ross DS, Daniels GH, De Stefano P, Maloof F, Ridgway EC: Use of adjunctive potassium iodide after radioactive iodine (131I) treatment of Graves' hyperthyroidism. J Clin Endocrinol Metab 1983, 57:250-253.
• [70]Rappaport B, Caplan R, De Groot LJ: Low-dose sodium iodine I 131 therapy in Graves disease. JAMA 1973, 224:1610-1613.
• [71]Sridama V, DeGroot LJ: Treatment of Graves' disease and the course of opthalmopathy. Am J of Med 1989, 87:70-73.
• [72]Goolden AW, Stewart JS: Long-term results from graded low dose radioactive iodine therapy for thyrotoxicosis. Clin Endocrinol (Oxf) 1986, 24:217-222.
• [73]McCullagh EP, Jelden GL, Rodriguez-Antunez A: Incidence of hypothyroidism following small doses of 131I in the treatment of Graves' disease. Oh State Med J 1976, 72:538-540.
• [74]Dobyns BM: Radiation effects on the thyroid. Effects vary with dosage and sensitivity of the gland to radiation. RI Med J 1975, 58(94–7):122-125.
• [75]Safa AM: Treatment of hyperthyroidism with a large initial dose of sodium iodine I 131. Arch Intern Med 1975, 135:673-675.
• [76]Chiovato L, Fiore E, Vitti P, Rocchi R, Rago T, Dokic D, Latrofa F, Mammoli C, Lippi F, Ceccarelli C, Pinchera A: Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage. J Clin Endocrinol Metab 1998, 83:40-46.
• [77]Murakami Y, Takamatsu J, Sakane S, Kuma K, Ohsawa N: Changes in thyroid volumes in response to radioactive iodine for Graves' hyperthyroidism correlated with activity of throid-stimulatinf antibody and treatment outcome. J Clin Endocrinol Metab 1996, 81:3257-3260.
• [78]Hancock LD, Tuttle RM, LeMar H, Baumen J, Patience T: The effect of propylthiouracil on subsequent radioactive iodine therapy in Graves' disease. Clin Endocrinol (Oxf) 1997, 47:425-430.
• [79]Allahabadia A, Daykin J, Sheppard MC, Gough SC, Franklyn JA: Radioiodine treatment of hyperthyroidism-prognostic factors for outcome. J Clin Endocrinol Metab 2001, 86:3611-3617.
• [80]Ueda D: Normal volume of the thyroid gland in children. J Clin Ultrasound 1990, 18:455-462.
• [81]Vitti P, Martino E, Aghini-Lombardi F, Rago T, Antonangeli L, Maccherini D, Nanni P, Loviselli A, Balestrieri A, Araneo G: Thyroid volume measurement by ultrasound in children as a tool for the assessment of mild iodine deficiency. J Clin Endocrinol Metab 1994, 79:600-603.
• [82]Crile G, Schumacher OP: Radioactive iodine treatment of Graves' disease. Results in 32 children under 16 years of age. Am J Dis Child 1965, 110:501-504.
• [83]Hayek A, Chapman EM, Crawford JD: Long term results of treatment of thyrotoxicosis in children and adolescents with radioactive iodine (131I) for hyperthyroidism. N Engl J Med 1970, 283:949-953.
• [84]Freitas JE, Swanson DP, Gross MD, Sisson JC: Iodine131-I: optimal therapy for thyroidism in children and adolescents? J Nucl Med 1979, 20:847-850.
• [85]Starr P, Jaffe HL, Oettinger L Jr: Late results of 131I treatment of hyperthyroidism in 73 children and adoloscents. J Nucl Med 1964, 5:81-89.
• [86]Starr HJ, Oettinger L Jr: Later results of 131-I treatment of hyperthyroidism in 73 children and adolescence: 1967 follow-up. J Nucl Med 1969, 10:586-590.
• [87]Kogut MD, Kaplan SA, Collipp PJ, Tiamsic T, Boyle D: Treatment of hyperthyroidism in children: analysis of fourty-five patients. N Engl J Med 1965, 272:217-222.
• [88]Moll GW Jr, Patel BR: Pediatric Graves' Disease: therapeutic options and experinence with radioiodine at the University of Mississippi Medical center. South Med J 1997, 90:1017.
• [89]Safa AM, Schumacher OP, Rodriguez-Antunez A: Long-term follow-up results in children and adolescents treated with radioactive iodine (131I) for hyperthyroidism. N Engl J Med 1975, 292:167-171.
• [90]Rivkees SA, Cornelius EA: Influence of iodine-131 dose on the outcome of hyperthyroidism in children. Pediatrics 2003, 111:745-749.
• [91]Nebesio TD, Siddiqui AR, Pescovitz OH, Eugster EA: Time course to hypothyroidism after fixed-dose radioablation therapy of Graves' disease in children. J Pediatr 2002, 141:99-103.
• [92]Kalinyak JE, McDougall IR: How should the dose of iodine-131 be determined in the treatment of Graves' hyperthyroidism? J Clin Endocrinol Metab 2003, 88:975-977.
• [93]Leslie WD, Ward L, Salamon EA, Ludwig S, Rowe RC, Cowden EA: A randomized comparison of radioiodine doses in Graves' hyperthyroidism. J Clin Endocrinol Metab 2003, 88:978-983.
• [94]Barnes HV, Blizzard RM: Antithyroid drug therapy for toxic diffuse goiter (Graves disease): thirty years experience in children and adolscence. J Pediatr 1977, 91:313-320.
• [95]Miccoli P, Vitti P, Rago T, Iacconi P, Bartalena L, Bogazzi F, Fiore E, Valeriano R, Chiovato L, Rocchi R, Pinchera A: Surgical treatment of Graves' disease: subtotal or total thyroidectomy? Surgery 1996, 120:1020-1024. discussion 4–5
• [96]Wiersinga WM, Prummel MF: Graves' ophthalmopathy: A rational approach to treatment. Trends Endocrinol Metab 2002, 13:280-287.
• [97]Sarkar SD, Beierwaltes WH, Gill SP, Cowley BJ: Subsequent fertility and birth histories of children and adolescents treated with 131I for thyroid cancer. J Nucl Med 1976, 17:460-464.
• [98]Boice JD Jr: Radiation-induced thyroid cancer–what's new? J Natl Cancer Inst 2005, 97:703-705.
• [99]Boice JD Jr: Thyroid disease 60 years after Hiroshima and 20 years after Chernobyl. JAMA 2006, 295:1060-1062.
• [100]Ron E, Lubin JH, Shore RE, Mabuchi K, Modan B, Pottern LM, Schneider AB, Tucker MA, Boice JD Jr: Thyroid Cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res 1995, 141:259-277.
• [101]Dolphin GW: The risk of thyroid cancers following irradiation. Health Phys 1968, 15:219-228.
• [102]Sigurdson AJ, Ronckers CM, Mertens AC, Stovall M, Smith SA, Liu Y, Berkow RL, Hammond S, Neglia JP, Meadows AT, Sklar CA, Robison LL, Inskip PD: Primary thyroid cancer after a first tumour in childhood (the Childhood Cancer Survivor Study): a nested case–control study. Lancet 2005, 365:2014-2023.
• [103]Flynn RW, Macdonald TM, Jung RT, Morris AD, Leese GP: Mortality and vascular outcomes in patients treated for thyroid dysfunction. J Clin Endocrinol Metab 2006, 91:2159-2164.
• [104]Franklyn JA, Maisonneuve P, Sheppard MC, Betteridge J, Boyle P: Mortality after the treatment of hyperthyroidism with radioactive iodine. N Engl J Med 1998, 338:712-718.
• [105]Franklyn JA, Sheppard MC, Maisonneuve P: Thyroid function and mortality in patients treated for hyperthyroidism. JAMA 2005, 294:71-80.
• [106]Goldman MB, Monson RR, Maloof F: Cancer mortality in women with thyroid disease. Cancer Res 1990, 50:2283-2289.
• [107]Holm LE, Hall P, Wiklund K, Lundell G, Berg G, Bjelkengren G, Cederquist E, Ericsson UB, Hallquist A, Larsson LG: Cancer risk after iodine-131 therapy for hyperthyroidism. J Natl Cancer Inst 1991, 83:1072-1077.
• [108]Metso S, Jaatinen P, Huhtala H, Auvinen A, Oksala H, Salmi J: Increased cardiovascular and cancer mortality after radioiodine treatment for hyperthyroidism. J Clin Endocrinol Metab 2007, 92:2190-2196.
• [109]Ron E, Doody MM, Becker DV, Brill AB, Curtis RE, Goldman MB, Harris BS 3rd, Hoffman DA, McConahey WM, Maxon HR, Preston-Martin S, Warshauer ME, Wong FL, Boice JD Jr: Cancer mortality following treatment for adult hyperthyroidism. Cooperative Thyrotoxicosis Therapy Follow-up Study Group. JAMA 1998, 280:347-355.
• [110]Read CH Jr, Tansey MJ, Menda Y: A thirty-six year retrospective analysis of the efficacy and safety of radioactive iodine in treating young Graves' pateints. JCEM 2004, 89(9):4229-4233.
• [111]Toohey RE, Stabin MG, Watson EE: The AAPM/RSNA physics tutorial for residents: internal radiation dosimetry: principles and applications. Radiographics 2000, 20:533-546.
• [112]Toohey RE, Stabin MG: Comparative analysis of dosimetry parameters for nuclear medicine. ORISE Report 99–1064, 1999. In Proceedings of the Sixth International Radiopharmaceutical Dosimetry Symposium. Gatlinburg, TN; 1996:532-551.
• [113]Health Risks from Exposure to Low Levels of Ionizing Radiation: BEIR VII – Phase 2. Washington D.C: National Academies Press; 2006.
• [114]Ching T, Warden MJ, Fefferman RA: Thyroid surgery in children and teenagers. Arch Otolaryngol 1977, 103:544-546.
• [115]Buckingham BA, Costin G, Roe TF, Weitzman JJ, Kogut MD: Hyperthyroidism in children. A reevaluation of treatment. Am J Dis Child 1981, 135:112-117.
• [116]Rudberg C, Johansson H, Akerstrom G, Tuvemo T, Karlsson FA: Graves' disease in children and adolescents. Late results of surgical treatment. Eur J Endocrinol/Eur Fed Endocr Soc 1996, 134:710-715.
• [117]Peters H, Fischer C, Bogner U, Reiners C, Schleusener H: Reduction in thyroid volume after radioiodine therapy of Graves' hyperthyroidism: results of a prospective, randomized, multicentre study. Eur J Clin Invest 1996, 26:59-63.
• [118]Sosa JA, Tuggle CT, Wang TS, Thomas DC, Boudourakis L, Rivkees S, Roman SA: Clinical and economic outcomes of thyroid and parathyroid surgery in children. J Clin Endocrinol Metab 2008, 93:3058-3065.
• [119]Breuer CK, Solomon D, Donovan P, Rivkees SA, Udelsman R: Effect of patient Age on surgical outcomes for Graves' disease: a case–control study of 100 consecutive patients at a high volume thyroid surgical center. Int J Pediatr Endocrinol 2013, 2013:1.
• [120]Lal G, Ituarte P, Kebebew E, Siperstein A, Duh QY, Clark OH: Should total thyroidectomy become the preferred procedure for surgical management of Graves' disease? Thyroid 2005, 15:569-574.
• [121]Boger MS, Perrier ND: Advantages and disadvantages of surgical therapy and optimal extent of thyroidectomy for the treatment of hyperthyroidism. Surg Clin N Am 2004, 84:849-874.
• [122]Witte J, Goretzki PE, Dotzenrath C, Simon D, Felis P, Neubauer M, Röher HD: Surgery for Graves' disease: total versus subtotal thyroidectomy-results of a prospective randomized trial. World J Surg 2000, 24:1303-1311.
• [123]Sosa JA, Bowman HM, Tielsch JM, Powe NR, Gordon TA, Udelsman R: The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg 1998, 228:320-330.
• [124]Breuer C, Tuggle C, Solomon D, Sosa JA: Pediatric thyroid disease: when is surgery necessary, and who should be operating on our children? J Clin Res Pediatr Endocrinol 2013, 5(Suppl 1):79-85.
• [125]Peroni E, Angiolini MR, Vigone MC, Mari G, Chiumello G, Beretta E, Weber G: Surgical management of pediatric Graves' disease: an effective definitive treatment. Pediatr Surg Int 2012, 28:609-614.
• [126]Read CH Jr, Tansey MJ, Menda Y: A 36-year retrospective analysis of the efficacy and safety of radioactive iodine in treating young Graves' patients. J Clin Endocrinol Metab 2004, 89:4229-4233.
• [127]Wilkins L: The Diaganosis and Treatment of Endocrine Disorders in Children and Adolescence. Hypothyroidism. Charles Thomas, Springfield; 1965:141-150.
• [128]Davies T, Roti E, Braverman LE, De Groot LJ: Thyroid conterversy–stimulating antibodies. J Clin Endocrinol Metab 1998, 83:3777-3785.
• [129]Wilson R, McKilop JH, Henderson N, Pearson DW, Thomson JA: The ability of the serum throtrophin receptr antibody (TRAb) index and HLA status to predict long-term remission of thyrotoxicosis following medical therapy for Graves' disease. Clin Endocrinol (Oxf) 1986, 25(2):151-156.